Insmed Incorporated (NASDAQ:INSM) is one of the best stocks to invest in right now. On September 19, RBC Capital analyst Leonid Timashev maintained a Buy rating on Insmed Incorporated (NASDAQ:INSM) and set a price target of $138.00.
Insmed Incorporated reported in its fiscal Q2 2025 results that total revenue for ARIKAYCE reached $107.4 million for the quarter, reflecting a growth of 19% over fiscal Q2 2024.
Insmed Incorporated is a global biopharmaceutical company that develops and commercializes therapies for patients with rare diseases. The company focuses on the Brensocatib and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
